Praxis Precision Medicines, Inc. 8-K/A

What Happened

• Praxis Precision Medicines, Inc. (PRAX) amended a prior Form 8-K to report board committee assignments and changes to its non-employee director pay policy. The company originally disclosed the election of Jeffrey B. Kindler and Stuart A. Arbuckle as Class II directors effective January 8, 2026.
• On February 6, 2026, the Board, following committee recommendations, appointed Mr. Kindler to the Audit Committee and the Nominating and Corporate Governance Committee, and Mr. Arbuckle to the Compensation Committee and the Science and Technology Committee. On the same date the Board amended and restated the Company’s Non-Employee Director Compensation Policy.

Key Details

• Directors named: Jeffrey B. Kindler and Stuart A. Arbuckle; initial board seats effective January 8, 2026. Committee assignments effective February 6, 2026.
• Committee roles: Kindler — Audit Committee and Nominating Committee; Arbuckle — Compensation Committee and Science & Technology Committee.
• Compensation changes: Under the amended Non-Employee Director Compensation Policy (filed as Exhibit 99.1), both directors received initial awards of restricted stock units (RSUs) and stock options and are eligible for annual cash retainers and annual RSU and stock option awards.
• Filing: This information amends the company’s initial 8-K and was included in a Current Report on Form 8-K/A filed February 10, 2026.

Why It Matters

• Board composition and committee memberships affect oversight of financial reporting, executive pay and R&D strategy—areas directly relevant to governance and risk.
• The amended director compensation policy signals the company’s standard pay structure for non-employee directors and that new directors received equity and cash-based compensation, which can modestly dilute shares over time and align directors with shareholder interests.
• For investors, these are governance updates (not operational or financial results) worth noting when evaluating management oversight and potential future dilution from director equity awards.